First Horizon 13F: Adds $518K to Cardinal Health (CAH) Stake
Key Points
- First Horizon added 2,328 shares to its position in Cardinal Health, raising its total to 8,900 shares worth about $1.98 million.
- The stock closed at $252.18 on October 26, 2026, while recently trading around $249.57, about 1% lower than the closing price.
- Cardinal Health has a market cap of approximately $57.8 billion and is currently above its 50-day and 200-day moving averages.
Get Cardinal Health text alerts
We text you when insiders, Congress, analysts or big funds move on $CAH.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cardinal Health, Inc. alert may contain errors. Disclosures
First Horizon boosted its stake in Cardinal Health, Inc. (CAH) by 2,328 shares, bringing its total holdings to 8,900 shares valued at approximately $1.98 million as of September 30, 2026. This change was disclosed in a filing on October 26, 2026, with the stock closing at $252.18 that day.
CAH
Cardinal Health, Inc.
Where Cardinal Health Fits in First Horizon's Portfolio
First Horizon’s investment in Cardinal Health now represents 0.2% of its total reported value of about $988.7 million. The stock ranks 45th among the 1,514 positions in First Horizon's portfolio, and the increase in shares reflects a 35.4% rise in its investment.
Other Institutional Activity in Cardinal Health
Recently, Symphony Financial increased its holdings by 5,991 shares, totaling 9,615 shares worth about $2.14 million. Conversely, California State Teachers Retirement System reduced its stake by 9,726 shares to 370,711 shares valued at approximately $81.99 million. Janus Henderson Group also grew its position significantly, adding 559,450 shares for a total of 735,467 shares.
Cardinal Health, Inc. Stock Down 2.4%
As of October 27, 2026, Cardinal Health shares traded recently around $249.57, which is about 1% below the closing price of $252.18 on October 26. The stock is currently above its 50-day moving average by 5.6% and its 200-day moving average by 12.9%.
Recent Earnings
Cardinal Health reported trailing twelve-month revenue of about $254.2 billion, with an EPS of $7.23. The next earnings report is scheduled for November 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Insider Buying and Selling at Cardinal Health, Inc.
Recent insider transactions included several officers selling shares on August 18 and 19, 2026. Jessica L. Mayer sold 29,436 shares valued at about $6.95 million, while Stephen M. Mason sold 35,000 shares for approximately $8.27 million. These transactions occurred before the recent filing by First Horizon.
Analysts Set New Price Targets
On October 16, 2026, UBS maintained a Buy rating on Cardinal Health, raising its price target to $295. Mizuho also maintained an Outperform rating with a target of $280 on October 20. The consensus recommendation for Cardinal Health is a Buy, with a mean price target of about $273.47.
About Cardinal Health
Cardinal Health, Inc. operates in the healthcare sector, providing services and products to hospitals, pharmacies, and patients. The company has two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. This recent increase in First Horizon's stake may reflect confidence in Cardinal Health's growth prospects.
Bottom Line
Investors will be watching Cardinal Health's upcoming earnings report on November 5, 2026, as well as any further institutional moves in the stock. First Horizon's increase in shares adds to the ongoing interest in Cardinal Health's performance and future potential.
Related Filing Alerts
Source: First Horizon's 13F filing on $CAH (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts